Benzinga | Oct 1, 2021 06:51AM EDT

Immuneering Reports Will Present Preclinical Data Across Several Poster Presentations At AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Oct. 7-10

Preclinical Data Demonstrates Broad Antitumor Activity of IMM-1-104 Across RAS and RAF Mutant Tumors and Highlights Mechanistic Aspects of its Dual MEK Inhibition

Company to Host Key Opinion Leader Event on October 12, 2021 at 11:30 am Eastern Time

CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced that several key preclinical datasets highlighting the potential of its lead product candidate, IMM-1-104, will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place virtually from October 7-10, 2021.

IMM-1-104 is designed to be a highly selective dual-MEK inhibitor that further disrupts the kinase suppressor of RAS 1 and 2 (KSR1/2) for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. The Company anticipates submission of an Investigational New Drug application (IND) for IMM-1-104 to the U.S. Food and Drug Administration (FDA) in the first quarter of 2022.

The following posters featuring IMM-1-104 will be presented at EORTC 21:

IMM-1-104: a novel, oral, selective dual-MEK inhibitor thatTitle: displays broad antitumor activity and high tolerability across RAS and RAF mutant tumors in vivoPoster #: P252Presenter: Brett Hall, Ph.D., Chief Scientific Officer at Immuneering Title: Transcriptional effects in C26 tumor highlight mechanistic aspects of a novel dual MEK inhibitor, IMM-1-104Poster #: P254Presenter: Sarah Kolitz, Ph.D., Vice President, Translational Medicine, at Immuneering Benchmarking the novel dual-MEK inhibitor, IMM-1-104, head-to-headTitle: and in combination with sotorasib (AMG-510) in the MIA PaCa-2 (KRAS-G12C) pancreatic cancer xenograft modelPoster #: P240Presenter: Peter King, Ph.D., Vice President, Head of Discovery, at Immuneering

"We look forward to sharing data from multiple animal studies that we believe demonstrate IMM-1-104's potential for activity against a wide range of RAS and RAF mutant tumors," said Ben Zeskind, Ph.D., Co-Founder, President and Chief Executive Officer of Immuneering. "Equally important is the tolerability profile that we consistently observe across animal models. Taken together, we believe these results indicate that IMM-1-104 achieves a potentially attractive therapeutic index in a fundamentally new way through deep cyclic inhibition of the MAPK pathway that is not specific to any one mutation."

"The transcriptomic data that we are presenting demonstrates this novel mechanism. We are also presenting data showing synergy with sotorasib in an animal model of KRAS G12C mutant pancreatic cancer, and we believe IMM-1-104's broad activity also means it has the potential to overcome resistance frequently seen with registered KRAS and MEK inhibitors," added Dr. Zeskind.

Key Opinion Leader Event

Following the close of the conference, Immuneering management will host a Key Opinion Leader Event, which will review the presented data in greater detail and highlight its broader application and potential. Event details are below:

Title: Better Medicines for MEK, RAS and Beyond Through Signaling DynamicsDay/Time: October 12, 2021 from 11:30 am ? 1:00 pm Eastern TimePresenters: Alexander Spira, MD, PHD, FACP, Director of the Virginia Cancer Specialists Research Institute and US Oncology Research Anthony W. Tolcher, MD, FRCPC, FACP, FASCO, Director of Clinical Research Founder and CEO of NEXT OncologyRegistration: Better Medicines for MEK, RAS and Beyond Through Signaling Dynamics Registration (onlinexperiences.com)i